Repros gets partial reprieve on Proellex hold
This article was originally published in Scrip
The US FDA reclassified the clinical hold on Repros Therapeutics' studies for its orally selective progesterone antagonist Proellex from a full hold to partial status to permit the firm to conduct a Phase II study to test lower doses of the medicine in patients with endometriosis, a condition which affects about 5 million women of reproductive age in the US and Canada and is characterized by severe pelvic abdominal pain, which generally peaks during menses.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.